Liraglutide is the active ingredient in Saxenda. It's a glucagon-like peptide-1 (GLP-1) receptor agonist that can help with weight management. The other liraglutide is Victoza, which is made primarily for treating type 2 diabetes. Novo Nordisk manufactures both products.
Saxenda is included in a list of GLP-1 RAs that are facing over 1,300 lawsuits in court. The plaintiffs of these cases are alleging that manufacturers like Novo Nordisk and Eli Lilly failed to highlight that GLP-1 RAs can also cause gastrointestinal problems like gastroparesis, ileus, and bowel obstruction. These medications can also cause a form of vision loss.
If you believe you're suffering from any of these because of Victoza, you might be eligible for a claim. Reach out to our team with evidence that can prove this, such as prescription histories and medical records. After our assessments prove your eligibility, we'll put you in contact with an expert attorney immediately.